Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 10/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 7/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.53 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10793551 | 1.00 | CTSL (0.57) | CTSLP2RX7CTSBITGA4ITGB7 | |
| SCHEMBL7327394 | 1.00 | CTSL (0.57) | CTSLP2RX7CTSBITGA4ITGB7 | |
| SCHEMBL9334020 | 0.96 | CTSL (0.56) | CTSLP2RX7CTSBITGA4ITGB7 | |
| SCHEMBL2980678 | 0.91 | P2RX7 (0.49) | CTSLP2RX7CTSBITGA4ITGB7 | |
| SCHEMBL2980681 | 0.91 | P2RX7 (0.49) | CTSLP2RX7CTSBITGA4ITGB7 | |
| SCHEMBL31151026 | 0.90 | CASP1 (0.52) | CTSLP2RX7 | |
| SCHEMBL11415411 | 0.90 | CTSK (0.53) | CTSLP2RX7CTSBCTSK | |
| SCHEMBL8436808 | 0.90 | CTSL (0.62) | CTSLP2RX7CTSBITGA4ITGB7 | |
| SCHEMBL8433969 | 0.90 | CTSL (0.62) | CTSLP2RX7CTSBITGA4ITGB7 | |
| SCHEMBL8433892 | 0.90 | CTSL (0.62) | CTSLP2RX7CTSBITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117064910-A | Composite nano enzyme and preparation method and application thereof | 东南大学 | 2023-11-17 | — | — | CN | disclosed |
| EP-1481966-B1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2011-07-20 | — | — | EP | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-7291617-B2 | Arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-11-06 | — | — | US | disclosed |
| US-RE38796-E1 | Process for producing 3-amino-2-oxo-1-halogenopropane derivatives | AJINOMOTO CO.,INC. (JP) | 2005-09-13 | — | — | US | disclosed |
| EP-0839798-B1 | Intermediates for preparating non-peptide retroviral protease inhibitors | ABBOTT LAB (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | TOYAMA CHEMICAL CO., LTD (JP) | 2005-05-26 | — | — | US | disclosed |
| US-6890519-B2 | Silicone oil/cosolvent system concentrated in active liposoluble cosmetic substance(s), corresponding cosmetic emulsion and formulation | RHODIA CHIMIE (FR) | 2005-05-10 | — | — | US | disclosed |
| EP-1481966-A1 | NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-12-01 | — | — | EP | disclosed |
| EP-0142231-B1 | PROCESS FOR PRODUCING SEQUENTIAL POLYAMINO ACID RESIN | NITTO BOSEKI CO., LTD. (JP) | 1987-11-11 | — | — | EP | disclosed |
| EP-0144290-A2 | Substituted ethylenediamine derivatives | CIBA-GEIGY AG (CH) | 1985-06-12 | — | — | EP | disclosed |
| US-4440678-A | ARGININES | PENTAPHARM, A.G. (CH) | 1984-04-03 | — | — | US | disclosed |
| EP-0034122-A1 | Tripeptide derivatives and their use in the determination of enzymes | Pentapharm A.G. (CH) | 1981-08-19 | — | — | EP | disclosed |
| US-RE29369-E | AMIDE PRODUCT, SALTS OF HYDROXY-SUBSTITUTED PYRIDINE COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1977-08-23 | — | — | US | disclosed |
| US-4043992-A | Method for preparing acylated products | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1977-08-23 | — | — | US | disclosed |
| US-3984417-A | Method of producing active amino acid esters | AJINOMOTO CO., INC. (JA) | 1976-10-05 | — | — | US | disclosed |
| US-3976635-A | Novel esterifying agents, and their production and use | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1976-08-24 | — | — | US | disclosed |
| US-3963728-A | ACYLATION OF NITROGEN CONTAINING COMPOUNDS USING ESTERS | KYOWA HAKKO KOGYO CO., LTD. (JA) | 1976-06-15 | — | — | US | disclosed |
| US-3933783-A | Formation of peptide bonds in the presence of isonitriles | AJINOMOTO CO., INC. (JA) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113424-A1 | Novel arylamidine derivative or salt thereof | SLC7A1, NAT1, NACA | CTSL 1578/4885P2RX7 3881/4885CTSB 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.